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Studies of complementary and alternative ther-
apy (CAM) use among patients with cancer suggest
that these are used by a substantial proportion of
patients, although the ﬁgure varies considerably
across studies. We do know that CAM use is more
common among people who are younger, female,
or of higher socio-economic status and education
background. Users may be more likely to be anx-
ious or depressed, have a high belief in the ef-
ﬁcacy of CAM and a corresponding dissatisfaction
with conventional medicine. CAM is also known to
be used as an active method of coping with con-
ventional cancer treatment. However, studies ex-
amining the use of CAM among people with cancer
have limitations. Studies have relied heavily on sur-
vey methods which, although useful, tell us little
about the complex issues surrounding CAM use. Dis-
tinct motivations have been identiﬁed such as to
treat the disease or prevent cancer recurring, or
as an adjunct to conventional cancer treatment to
maximise quality of life or to assist in returning to
normal life after treatment.
We are undertaking a study of the use of CAM
among people undergoing cancer treatment funded
by the NHS R&D Programme. We are in the process
surveying a sample of 300 patients from twocancer
centres, stratiﬁed to represent the UK incidence
of cancer. We are also interviewing, using quali-
tative biographic narrative methods, a sub-sample
of 40 CAM users and 10 nonusers. The study is on-
going with 184 questionnaires completed to date.
Early ﬁndings from the survey suggest that there
are three types of CAM ‘user’. Firstly, individuals
who used CAM prior to their cancer diagnosis and
continue to use CAM afterwards. Secondly, individ-
uals who did not use CAM prior to their diagnosis
but have used it since, some of these individuals
have used CAM because it has been offered as part
of their treatment and support. Thirdly, people who
used CAM prior to their diagnosis but have stopped
since because of concerns over the safety or ap-
propriateness of combining CAM with conventional
cancer treatment.
It is possible to identify a number of drivers for
CAM use in cancer, both those that act to promote
CAM use, but also those that prevent or inhibit CAM
use. These include personal motivation, accessibil-
ity and availability of CAM, ﬁnancial resources, the
desire to actively manage one’s illness, availabil-
ity of evidence about the value and safety of CAM
as an adjunct to cancer treatment, and a lackof
informed guidance for patients.
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As an oncologist, I became involved in com-
plementary and alternative treatments (CAMs)
because my patients were using them.1 For this
reason our support care in the Lynda Jackson
Macmillan Centre at Mount Vernon Cancer Centre
included CAMs in the services offered. Between
1993 and 1998, we established a service model
housed in a new building, including supportive lis-
tening, high quality information, ‘‘touch, talkand
time’’ therapies and psychological support from
psychologists and psychiatrists. We were not alone,
as most cancer centres in the UK now employ at
least one CAM therapist. A key aspect of the success
of LJMC was its position as part of a large cancer
centre serving 5000 new patients with access to
25 oncologists in 15 district general hospital with
all their networks and nearly 50 clinical scientists.
This allowed exchange of learning between ortho-
dox and complementary practitioners and service
developers and researchers. Therapies were in-
troduced step-by-step focussing on developing
a shared language, understanding the therapy
from a range of perspectives and testing the use
of outcome measure and study designs which
produced data meaningful to all stakeholders.
During this work, we recognised the importance
of collaboration with academic centres with a wide
range of different expertise, of using the tools of
education and information as well as research to
change practice but also producing peer reviewed
publications. We recognised the need to workto-